Company Overview: Keryx Bio

About the Company

Keryx Bio
Tweeter Linkedin

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes.

The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City. Keryx is headquartered in New York City.


Investor Toolkit

Multimedia

Company News

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address